Veracyte
Highly Engaged Employees
Highly Engaged EmployeesBusiness Services · California, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
6000 Shoreline Ct Ste 300, South San Fra...Phone Number
(650) 243-6300Website
www.veracyte.comRevenue
$541.7 MillionStock Symbol
VCYTIndustry
ZI Rank: 2
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
3
3
1
5
1
2
About Veracyte
Founded in 2006, Veracyte is emerging in the field of molecular cytology by developing molecular tests designed to improve the diagnostic accuracy of cytology samples and also helping to increase the utility of minimally invasive procedures as an alternative to surgical biopsy. The company is headquartered in San Francisco, California.Explore more
Veracyte Org Chart
Get the full picture
Sign in to uncover key details.
Show More
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Veracyte your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Veracyte recently announced quarterly report
Funding: Get notified immidiatlly once Veracyte has new funding data
Product Launch: Get notified when Veracyte launches new products
Congratulate Masked Content for being promoted to Masked Content at Veracyte
Website visits: Recent activity has been detected on your website
Check out if Veracyte is spiking on competitors!
Click to see if Veracyte had a recent Job posting/layoffs
Veracyte, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Veracyte has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Veracyte
Find more new buyers
Compare Similar Companies to Veracyte
Compare insights from companies similar to Veracyte, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Veracyte is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Veracyte is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Veracyte.
Veracyte financials insights
Gather financial insights about Veracyte, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2010
Series B
$28M
2013
Series C
$28M
Stock Offering
$58M
2015
Share Placement
$40M
2016
Debt
$45M
Stock Offering
$31.9M
2018
Stock Offering
$55.1M
2019
Stock Offering
$137.9M
2020
Stock Offering
$194M
Veracyte Tech Stack
A closer look at the technologies used by Veracyte
See more technologies
Most Recent Scoops
Event
hosted a spotlight theater at the recent American Association for Cancer Research Annual Meeting in San Diego, where investigators presented data from multiple large clinical trials including TOMBOLA, UMBRELLA, and NEO-BLAST focused on the clinical utility of the TruMRD platform for tumor-informed ctDNA analysis.
Events
Project
Veracyte has announced plans to launch Prosigna LDT, a test built on the PAM50 signature that reports the 10-year probability of distant recurrence using intrinsic subtype and proliferation scores to inform treatment decisions for early-stage hormone receptor-positive breast cancer patients, targeting an addressable US market of approximately 225,000 patients diagnosed annually.
Medical Research
Event
will be presenting six studies at the upcoming AUA Annual Meeting, highlighting the Decipher Bladder portfolio's ability to advance personalized care in bladder cancer, including insights generated from the company's GRID research use-only database.
Medical Research
Project
remains on track to launch TruMRD, its whole genome sequence-based minimal residual disease platform, in muscle-invasive bladder cancer by the end of Q2 2026, with an initial focus on recurrence monitoring in patients who have completed curative intent therapy.
Project
Medical Research
Veracyte News & Media
Marc Stapley – Chief Executive Officer - CEO - Veracyte
Veracyte Chief Executive Officer, CEO, Marc Stapley, has led the company since 2021 with significant expertise building and leading complex global enterprises.How Veracyte's New AI-Focused CTO Role At Veracyte (VCYT) Has Changed Its Investment Story
Veracyte, Inc. recently appointed Kevin Haas, Ph.D., as its first Chief Development and Technology Officer, tasking him with overseeing end-to-end product development across diagnostic assays, software, bioinformatics and program management to support its expanding global portfolio of laboratory-developed tests and in vitro diagnostic products. This new role, filled by a leader with deep experience in automated lab technology, AI and genomics platforms, underscores Veracyte’s intent to more...Veracyte, Inc. (VCYT) Q4 2025 Earnings Call Transcript
Veracyte, Inc. (VCYT) Q4 2025 Earnings Call February 25, 2026 4:30 PM ESTCompany ParticipantsShayla Gorman - Director of Investor RelationsMarc Stapley -...UBS Reaffirmed Buy Rating on Veracyte (VCYT) After Strong Q4 Testing Revenue
Veracyte, Inc. (NASDAQ:VCYT) ranks among the best innovative stocks to buy according to Wall Street analysts. On January 12, UBS reaffirmed its Buy rating for Veracyte, Inc. (NASDAQ:VCYT) alongside a price target of $48. Analyst Lu Li retained a favorable outlook after Veracyte’s Q4 testing revenue exceeded expectations, which the company attributed mostly to higher […]
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Veracyte
Sign Up For FreeTo access detailed company insights
Founded in 2006, Veracyte is emerging in the field of molecular cytology by developing molecular tests designed to improve the diagnostic accuracy of cytology samples and also helping to increase the utility of minimally invasive procedures as an alternative to surgical biopsy. The company is headquartered in San Francisco, California.... Read More
